GlassScriptPhysician profile
Raghav Bansal
NPI 1144547050
$60,288.43
in general payments reported to CMS, 2019-2025
22 companies · $6,497 in 2025
The $6,497 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $5,883 · 2021: $8,564 · 2022: $12K · 2023: $5,810 · 2024: $5,245 · 2025: $6,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $3,448 · Travel and Lodging: $550 · Education: $53.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $3,448.29 |
| Travel and Lodging | $550.19 |
| Education | $53.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52,305.13 | 2019-2025 | Mavyret, Creon, Linzess |
| Shionogi INC | $4,125.77 | 2019 | |
| Boston Scientific Corporation | $1,265.46 | 2022-2025 | Exalt Model D, Habib Endohpb, Compliance Endokit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $588.39 | 2023-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $411.36 | 2019-2025 | |
| Cook Medical LLC | $328.96 | 2024-2025 | Echotip Insight, Fusion Quattro, Fusion |
| Madrigal Pharmaceuticals | $271.49 | 2024-2025 | Rezdiffra |
| Olympus America INC. | $209.70 | 2024-2025 | Endoclot Phs, Single Use Repositionable Clip |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Pfizer INC. | $119.74 | 2025 | |
| Shire North American Group INC | $73.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.19 | 2022-2023 | |
| Janssen Biotech, INC. | $53.99 | 2025 | Tremfya |
| Ardelyx, INC. | $34.96 | 2025 | Ibsrela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.13 | 2024 | Entyvio |
| Dynavax Technologies Corporation | $29.78 | 2023 | Heplisav-B |
| W. L. Gore & Associates, INC. | $29.72 | 2022 | |
| Insmed, INC. | $29.03 | 2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $26.06 | 2023 | Xarelto |
| Exact Sciences Corporation | $25.19 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raghav Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.